Immunotherapy for Gastroesophageal Tumors: Is There Still Hope for Efficacy?

被引：0
作者：
Puhr, Hannah Christina [1 ]
Ilhan-Mutlu, Aysegul [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria
来源：
CURRENT CANCER DRUG TARGETS | 2022年 / 22卷 / 08期
关键词：
Esophageal neoplasm; stomach neoplasm; immunotherapy; immunogenic cell death; gastroesophageal cancer; gastric cancer; esophageal cancer; EPSTEIN-BARR-VIRUS; ADVANCED GASTRIC-CANCER; 1ST-LINE 1L TREATMENT; TO-LYMPHOCYTE RATIO; JUNCTION CANCER; MICROSATELLITE INSTABILITY; PLUS CHEMOTHERAPY; PROGNOSTIC VALUE; PD-1; BLOCKADE; SINGLE-ARM;
D O I：
10.2174/1568009622666220117101105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy represents one of the biggest breakthroughs of the 21st century and redefined modern cancer treatment. Despite this new approach changing the treatment paradigm in various cancer entities, including lung and head-and-neck cancer, the efficacy of these treatment regimens varies in different patient subgroups, and so far, these treatment regimens have failed to meet the high expectations of gastroesophageal cancer patients. This review discusses new treatment approaches concerning immunotherapy in gastroesophageal cancer patients and sheds some light on ongoing trials and new treatment combinations.
引用
收藏
页码：651 / 666
页数：16
相关论文
共 103 条
[1]   FRACTION (Fast Real-time Assessment of Combination Therapies in Immu no-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC. [J].
Aanur, Praveen ;
Gutierrez, Martin ;
Kelly, Ronan Joseph ;
Ajani, Jaffer A. ;
Ku, Geoffrey Yuyat ;
Denlinger, Crystal Shereen ;
George, Thomas J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2]  
Agency E.M, 2020, OPDIVO PENDING EC DE
[3]   Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO. [J].
Al-Batran, Salah-Eddin ;
Pauligk, Claudia ;
Goetze, Thorsten Oliver ;
Riera-Knorrenschild, Jorge ;
Goekkurt, Eray ;
Angermeier, Stefan ;
Kullmann, Frank ;
Thuss-Patience, Peter C. ;
Homann, Nils ;
Ettrich, Thomas Jens ;
Junge, Sabine ;
Hofheinz, Ralf ;
Lorenzen, Sylvie .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4]   Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. [J].
Al-Batran, Salah-Eddin ;
Pauligk, Claudia ;
Hofheinz, Ralf ;
Lorenzen, Sylvie ;
Wicki, Andreas ;
Siebenhuener, Alexander Rheinhard ;
Schenk, Michael ;
Welslau, Manfred ;
Heuer, Vera ;
Goekkurt, Eray ;
Schmalenberg, Harald ;
Thuss-Patience, Peter C. ;
Waberer, Lisa ;
Talbot, Jonathan ;
Goetze, Thorsten Oliver ;
Homann, Nils .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5]   LAG3 (CD223) as a cancer immunotherapy target [J].
Andrews, Lawrence P. ;
Marciscano, Ariel E. ;
Drake, Charles G. ;
Vignali, Dario A. A. .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96
[6]  
[Anonymous], 2020, ADM FAD FDA APPROVES
[7]  
[Anonymous], SEER Cancer Stat Facts: Prostate Cancer
[8]  
Bang Y-J, 2018, ANN ONCOL, V29, pviii268, DOI DOI 10.1093/ANNONC/MDY282.167
[9]   Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). [J].
Bang, Yung-Jue ;
Golan, Talia ;
Lin, Chia-Chi ;
Dahan, Laetitia ;
Fu, Siqing ;
Moreno, Victor ;
Geva, Ravit ;
Reck, Martin ;
Wasserstrom, Heather Ann ;
Mi, Gu ;
Laing, Naomi ;
Goff, Laura Williams .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
12345678910